Cardiawave SA, a deeptech medical device manufacturer that developed Valvosoft, a non-invasive medical device to treat aortic stenosis, announced the issuance of three new patents in the United States.
These patents protect Valvosoft’s ultrasound imaging and therapy device and its medical applications and are aimed to strengthen Cardiawave’s U.S. patent portfolio for its innovative non-invasive treatment of heart valve diseases and other cardiovascular applications.
- The first U.S. patent protects Cardiawave’s ultrasound imaging and therapy device, and more specifically the system that allows an optimal imaging for safety and performance purposes by keeping the ultrasound imaging probe stationary and in direct with the patient’s chest while the ultrasound therapeutical transducer treats different target zones.
- The second U.S. patent protects the technology and the means to detect and monitor with ultrasound imaging the cavitation bubbles which create the therapeutic effect generated by the emission of focused ultrasound.
- The third U.S. patent protects the entire apparatus for treating deep vein thrombosis with focused ultrasounds.
Cardiawave intends to bring its medical device to the American market to treat aortic stenosis which remains an immense unmet medical need in spite of the development of TAVR, the company says. A large number of patients diagnosed with severe aortic stenosis in their 80s are not treated in the U.S.: about 78% aged 70-79 and 84% aged 80-89 which represent approximately 200,000 patients in their 80’s untreated (2022 TCT presentation, 2021 figures).
Cardiawave is currently carrying out a pivotal clinical study in Europe, in order to obtain the CE marking and launch the commercialization of its device.
“We are thrilled to receive these new patents for our innovative solution to treat non-invasively aortic stenosis and other cardiovascular diseases,” says Benjamin Bertrand, CEO of Cardiawave. “Our IP portfolio is a key asset for our future development. We will continue to build high barriers to entry to protect our market from competition. Our team has worked tirelessly to bring this innovative technology to life, and we are proud to bring it soon to the market to help patients who suffer from this life-threatening condition.”